Wei Yang

Post-Doctoral Fellow, Memorial Sloan Kettering Cancer Center

I majored in pharmacy in college and have been fascinated with drug development since then. PEMM offers a broad range of preclinical and translational research opportunities related to drug discovery and development, from which I benefited the most here. Besides, due to the relative small scale of PEMM, students are more closely mentored by their advisors and we feel like a big family. This definitely helped me go through the ups and downs of PhD study! Currently, I am a postdoctoral research fellow at MSKCC, working on cancer neoantigen identification for the development of personalized cancer immunotherapy.


  • PhD, '17, Program in Experimental and Molecular Medicine, Dartmouth College
  • BS, '09, Zhejiang University

Selected Publications

  • Yang W, Hosford SR, Dillon LM, Shee K, Liu SC, Bean JR, Salphati L, Pang J, Zhang X, Nannini MA, Demidenko E, Bates DJ, Lewis LD,Marotti JD, Eastman A, Miller TW. Strategically timing inhibition of phosphatidylinositol 3-kinase to maximize therapeutic index in estrogen receptor alpha-positive, PIK3CA-mutant breast cancer. Clin Cancer Res. 2016.

  • Dillon LM, Bean JR, Yang W, Shee K, Symonds LK, Balko JM, McDonald WH, Liu S, Gonzalez-Angulo AM, Mills GB, Arteaga CL, Miller TW. P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer. Oncogene. 2015;34:3968-76.

  • Bean JR, Hosford SR, Symonds LK, Owens P, Dillon LM, Yang W, Shee K, Schwartz GN, Marotti JD, Muller KE, Rosenkranz KM, Barth RJ, Chen VS, Agarwal VR, Miller TW. The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer. Breast Cancer Res Treat. 2015;149:69-79.

  • Yang W, Chamberlin MD, Miller TW. Treatment strategies for hormone receptor-positive, HER2-negative advanced breast cancer. J OncoPathology, Volume 2, Number 2, 2014, pp. 33-42(10).


Dartmouth Graduate Student Travel Award, 2014